Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Postembolic pulmonary hypertension].

X Jais1, P Dartevelle, F Parent

  • 1Centre de Référence de l'Hypertension Artérielle Pulmonaire, Unité Propre de Recherche de l'Enseignement Supérieur EA2705, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Clamart, France. xavier.jais@abc.aphp.fr

Revue Des Maladies Respiratoires
|May 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?

ESMO open·2025
Same author

Combined multimodal therapy in high-risk patients with chronic thromboembolic pulmonary hypertension and both distal and proximal lesions: A prospective observational cohort study.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2025
Same author

Outcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2024
Same author

Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project.

ESMO open·2024
Same author

[Acute respiratory distress due to tracheostomy tube migration].

Revue des maladies respiratoires·2024
Same author

[Pulmonary complications of Chronic Granulomatous Disease].

Revue des maladies respiratoires·2024
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Pulmonary endarterectomy (PEA) is the primary treatment for chronic thromboembolic pulmonary hypertension (CTEPH). Further research is needed for inoperable cases and post-surgery persistent pulmonary hypertension.

Area of Science:

  • Cardiology
  • Pulmonology
  • Vascular Surgery

Background:

  • Chronic thromboembolic pulmonary hypertension (CTEPH) involves persistent clots in pulmonary arteries, leading to pulmonary hypertension and right heart failure.
  • Diagnosis is challenging due to lack of history in over 50% of cases, relying on V/Q scans, CT, and pulmonary angiography.
  • Right heart catheterization confirms PH and hemodynamic impairment, guiding treatment decisions.

Purpose of the Study:

  • To outline the diagnostic and treatment strategies for chronic thromboembolic pulmonary hypertension (CTEPH).
  • To highlight pulmonary endarterectomy (PEA) as the preferred treatment for eligible patients.
  • To identify areas requiring further research, particularly for inoperable CTEPH and post-surgical management.

Main Methods:

Related Experiment Videos

  • Diagnostic workup includes ventilation-perfusion scanning, CT angiography, and right heart catheterization.
  • Treatment decisions are based on the correlation between pulmonary vascular resistance and anatomical obstruction.
  • Pulmonary endarterectomy (PEA) is considered when anatomical obstruction correlates with hemodynamic impairment.

Main Results:

  • Pulmonary endarterectomy (PEA) is the treatment of choice for patients with operable CTEPH.
  • Medical therapies (vasodilators, antiproliferatives) and lung transplantation are alternatives for inoperable cases.
  • Hemodynamic assessment is crucial for determining operability and guiding treatment selection.

Conclusions:

  • Pulmonary endarterectomy (PEA) remains the gold standard for eligible CTEPH patients.
  • Randomized trials are needed to evaluate novel medical therapies for inoperable CTEPH, as a bridge to PEA, and for persistent PH post-surgery.
  • Further research is essential to optimize treatment strategies for complex CTEPH cases.